STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLPT
  4. [Form 4] ClearPoint Neuro, Inc. Insider Trading Activity

ClearPoint Neuro (CLPT) CBO granted 51,546 RSUs in multi-year vesting award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

STIGALL L. JEREMY reported acquisition or exercise transactions in this Form 4 filing.

ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall received a grant of 51,546 restricted stock units of ClearPoint Neuro common stock. Each unit represents the right to receive one share of CLPT common stock at vesting. The award vests over three years: 20% of the units on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029, aligning a substantial portion of his compensation with the company’s long-term performance.

Positive

  • None.

Negative

  • None.
Insider STIGALL L. JEREMY
Role Chief Business Officer
Type Security Shares Price Value
Grant/Award Restricted Stock Units 51,546 $0.00 --
Holdings After Transaction: Restricted Stock Units — 51,546 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
STIGALL L. JEREMY
(Last) (First) (Middle)
C/O CLEARPOINT NEURO, INC.
120 S. SIERRA AVE., SUITE 100
(Street)
SOLANA BEACH CA 92075
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Business Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 02/17/2026 A 51,546 (2) (2) Common Stock 51,546 $0 51,546 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.
2. The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029.
/s/ Danilo D'Alessandro, by Power of Attorney for Jeremy L. Stigall 02/19/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report for L. Jeremy Stigall?

ClearPoint Neuro reported that Chief Business Officer L. Jeremy Stigall was granted 51,546 restricted stock units. These units represent a right to receive an equal number of CLPT common shares, providing equity-based compensation tied to ClearPoint Neuro’s future performance and tenure.

How many restricted stock units were granted to the ClearPoint Neuro (CLPT) Chief Business Officer?

The Chief Business Officer received 51,546 restricted stock units of ClearPoint Neuro common stock. This entire amount reflects a single equity award, giving him the potential to receive 51,546 CLPT shares if vesting requirements are fully satisfied over time.

When do L. Jeremy Stigall’s ClearPoint Neuro (CLPT) restricted stock units vest?

The restricted stock units vest in three tranches: 20% on February 17, 2027, 40% on February 17, 2028, and 40% on February 17, 2029. This multi-year schedule encourages long-term alignment between the executive and ClearPoint Neuro shareholders.

What does each ClearPoint Neuro (CLPT) restricted stock unit granted to L. Jeremy Stigall represent?

Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro common stock. The units convert into actual CLPT shares only as they vest over time, subject to the specified vesting dates and applicable continued service requirements.

Is L. Jeremy Stigall’s ClearPoint Neuro (CLPT) restricted stock unit grant a purchase or an award?

The transaction is an award of 51,546 restricted stock units, not an open-market purchase. It is coded as a grant or other acquisition, indicating compensation-based equity granted at no cash cost per unit to the executive at the grant date.

How many ClearPoint Neuro (CLPT) derivative securities does L. Jeremy Stigall hold after this RSU grant?

Following this grant, L. Jeremy Stigall beneficially holds 51,546 restricted stock units as a derivative security position. These units are subject to the outlined vesting schedule before they can settle into ClearPoint Neuro common shares, assuming vesting conditions are met.